

1 **Prevalence of Post COVID-19 Condition among healthcare workers: self-reported**  
2 **online survey in four African countries**

3 Hager Elnadi,<sup>1</sup> Ahmad I. Al-Mustapha,<sup>1,2,3\*</sup> Ismail A. Odetokun,<sup>4</sup> AbdulAzeez Adeyemi Anjorin,<sup>5</sup>  
4 Rasha Mosbah,<sup>6,7</sup> Folorunso O. Fasina,<sup>8,9</sup> Youssef Razouqi,<sup>10</sup> Kwame Sherrif Awiagah,<sup>11</sup> Jean  
5 Baptiste Nyandwi,<sup>12</sup> Zuhail E. Mhgoob,<sup>13</sup> George Gachara,<sup>14</sup> Mohamed Farah Yusuf Mohamud<sup>15,16</sup>  
6 Bamu F. Damaris<sup>17</sup> Aala MohamedOsman Maisara<sup>18</sup> Mona Radwan<sup>19</sup>

7 <sup>1</sup> Infectious Disease and One Health, Faculty of Pharmaceutical Sciences, Universite de Tours,  
8 France.

9 <sup>2</sup> Department of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development,  
10 Ilorin, Nigeria.

11 <sup>3</sup> Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine,  
12 University of Helsinki, Finland.

13 <sup>4</sup> Department of Veterinary Public Health & Preventive Medicine, Faculty of Veterinary Medicine,  
14 University of Ilorin, Nigeria

15 <sup>5</sup> Department of Microbiology (Virology Research), Lagos State University, Nigeria

16 <sup>6</sup> Faculty of Oral and Dental Medicine, Ahram Canadian University, Egypt

17 <sup>7</sup> Infection Control Unit, Zagazig University, Zagazig, Egypt.

18 <sup>8</sup> Emergency Centre for Transboundary Animal Diseases (ECTAD), Food and Agricultural  
19 Organization of the United Nations (FAO), Tanzania.

20 <sup>9</sup> Department of Veterinary Tropical Disease, University of Pretoria, Pretoria, South Africa

21 <sup>10</sup> Biological Engineering Laboratory, Sultan Moulay Slimane University Beni Mellal, Morocco

22 <sup>11</sup> Training and Research Unit, Korle Bu Teaching Hospital, Ghana

23 <sup>12</sup> Department of Pharmacy, University of Rwanda, Rwanda.

24 <sup>13</sup> Department of Public Health & Infection Control, Aljawda Hospital & El Nileen University  
25 Community Development College, Khartoum, Sudan

26 <sup>14</sup> Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya.

27 <sup>15</sup> Department of Emergency Medicine at Mogadishu Somali Turkish Training and Research Hospital,  
28 Mogadishu, Somalia

29 <sup>16</sup> Department of Research at Jazeera University, Mogadishu, Somalia

30 <sup>17</sup> Hannover Medical School, Hannover, Germany.

31 <sup>18</sup> Department of Nephrology and Hemodialysis, International University of Africa, Khartoum, Sudan

32 <sup>19</sup> Department of Public Health, Faculty of Medicine, Zagazig University, Egypt

33

34 Corresponding author:

35 Ahmad I. Al-Mustapha ([ahmad.al-mustapha@helsinki.fi](mailto:ahmad.al-mustapha@helsinki.fi), [ai.almustapha42@gmail.com](mailto:ai.almustapha42@gmail.com) )

36

37 **Abstract**

38 The impact of Post COVID-19 Condition is ongoing despite the WHO declaration that the  
39 pandemic has ended. In this study, we explore the prevalence of PCC among healthcare  
40 workers (HCWs) in four African Countries and its influence on their professional performance.  
41 This study was conducted as an online cross-sectional survey of healthcare workers from four  
42 African countries (Cameroon, Egypt, Nigeria, and Somalia) between the 20<sup>th</sup> of December  
43 2021 to 12<sup>th</sup> of January 2022. We determined the prevalence of PCC based on the WHO case  
44 definition and assessed variables associated with a higher prevalence of PCC in these countries  
45 using univariable and multivariable logistic regression analyses. A total of 706 HCWs from  
46 four African countries were included in this survey. Most of the HCWs were aged between 18-  
47 34 years (75.8%, n=535). Our findings showed that 19.5% (n=138) of the HCWs had tested  
48 positive for SARS-CoV-2. However, 8.4% (n=59) were symptomatic for COVID-19 but tested  
49 negative or were never tested. Two-thirds of the HCWs (66.4%, n=469) have received a  
50 COVID-19 vaccine and 80.6% (n=378) of those vaccinated had been fully vaccinated. The  
51 self-reported awareness rate of PCC among the HCWs was 16.1% (n=114/706) whereas the  
52 awareness rate of PCC among COVID-19-positive HCWs was 55.3 % (n=109/197). The  
53 prevalence of PCC among HCWs was 58.8% (n=116). These changes include the self-reported  
54 symptoms of PCC which included headache (58.4%, n=115), fatigue (58.8%, n=116), and  
55 muscle pain (39.6%, n=78). Similarly, 30% (n=59) and 20.8% (n=41) of the HCWs reported  
56 the loss of smell and loss of taste long after their COVID-19 infection, respectively. Some  
57 HCWs (42%, n=83) believed that their work performance has been affected by their ongoing  
58 symptoms of PCC. There was no significant difference in the prevalence of PCC among the  
59 vaccinated and unvaccinated HCWs ( $p > 0.05$ ). Of the socio-demographic variables, age (older  
60 HCWs between 45-54 years; OR:1.7; 95% CI: 1.06, 10.59;  $p = 0.001$ ) and location (Egypt;  
61 OR:14.57; 95% CI: 2.62, 26.76;  $p = 0.001$ ) were more likely to have experienced PCC than  
62 other age groups and countries respectively. The study revealed low prevalence of PCC among  
63 the surveyed HCC. In addition, it observed the need for adequate medical and psychological  
64 support to HCWs with PCC, improve their COVID-19 vaccination uptake, and conduct mass  
65 advocacy campaigns on PCC.

66

67 **Keywords:** PCC, COVID-19, long-COVID, Africa, HCWs


68

69

70

71

72 Graphical abstract



73

74 COVID-19 positivity rate (n =197), vaccination rate (n =706), PCC awareness rate (n = 114),  
 75 and prevalence of PCC (n = 116) in HCWs across four African countries.

76

77

78

79

80

## 81 **1. Introduction**

82 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of  
 83 the 2019 coronavirus disease (COVID-19) pandemic. SARS-CoV-2 mainly affects the  
 84 respiratory system and the disease, COVID-19 has various clinical presentations, which vary  
 85 from mild to severe, especially among elderly and immunocompromised patients [1].

86 By 7<sup>th</sup> of June 2023, more than 767 million confirmed COVID-19 cases have been reported,  
 87 which has resulted in 6,941,095 million deaths globally. In Africa, COVID-19 reported cases

88 were around 9,534 million with 175,373 COVID-19-associated deaths (case fatality rate of 2%)  
89 [2]. To curb the spread of the SARS-CoV-2 virus, governments across the world initially  
90 instituted non-pharmaceutical interventions (the use of face masks, hand hygiene, physical  
91 distancing, and related measures) and later pharmaceutical interventions (mainly vaccines).  
92 The accelerating and efficient development, production, distribution, and acceptance of the  
93 COVID-19 vaccines have helped curb the disease spread, reduce hospitalization rates, and  
94 reduced the severity of the disease, particularly among infected patients [3]. The tremendous  
95 effect of the COVID-19 vaccines in reducing the disease transmission and the return of routine  
96 daily life worldwide, led to WHO's announcement on 5<sup>th</sup> of May 2023, that COVID-19  
97 pandemic is no longer a public health emergency [4].

98 After a COVID-19 infection, most of the ill patients return to their normal health status within  
99 days to a few weeks. However, some patients continue to suffer from ongoing, recurrent, or  
100 long-term health issues post-infection [5,6]. For instance, some patients were reported to  
101 experience a wide range of symptoms such as headache, fatigue, change in taste or smell,  
102 irregular menstruation, and mood changes among others, for months, post-infection [7-8].

103 To gain a significant understanding of these long-term COVID-19 adverse events, the World  
104 Health Organization (WHO) published a temporary clinical case definition for such cases,  
105 [5,9]. In October 2021, WHO announced that symptoms/signs which were previously termed  
106 long-term COVID-19, chronic COVID-19, or Post COVID-19 syndrome, are now identified  
107 as Post COVID-19 Condition (PCC) [5]. Despite the identification of these COVID-19  
108 sequelae as PCC by WHO, they lack clear classifications and several things remain unclear [5].  
109 For instance, the impact of vaccinations on the incidence of PCC requires further studies. Al-  
110 Aly et al.,[10] reported that COVID-19 vaccines reduced the likelihood of PCC in people who  
111 had been infected by only about 15% whereas Antonelli et al., reported that two doses of the  
112 COVID-19 vaccines halved the risk of PCC [11].

113 For instance, PCC had been reported in COVID-19 survivors regardless of their COVID-19  
114 severity (mild or severe), presentation (acute, sub-acute, or chronic), and whether the patient  
115 was hospitalized or not [8,9]. In addition, the PCC is similar to the post-SARS (severe acute  
116 respiratory syndrome coronavirus 1) and the Middle East Respiratory Syndrome Coronavirus  
117 (MERS CoV) syndromes (with symptoms such as fatigue, myalgia, psychiatric presentation,  
118 as well as pulmonary and bone complications) that have affected SARS, MERS CoV survivors  
119 for up to 4-15 years post-infection [12-18].

120 Given the insufficient information about its effects on individuals' health during the illness, or  
121 long after recovery, PCC may have a negative impact not only on the patient's health but also  
122 on their personal and professional life. Thus, the USA considered PCC a disability under the  
123 Americans with Disabilities Act (ADA) since July 2021 [4]. However, there is a paucity of  
124 reliable data about the COVID-19 pandemic and PCC in Africa. Therefore, this study assessed  
125 the prevalence of PCC and its association with the work performance of healthcare workers  
126 (HCWs) in four African countries.

127

128

## 129 **2. Materials and Methods**

### 130 **2.1 Ethical clearance**

131 The ethical clearance for this study was obtained from the Kwara State Ministry of Health,  
132 Ilorin, Nigeria with reference number MOH/KS/EHC/777/502 as well as the ethical review  
133 board of the Faculty of Human Medicine of the University of Zagazig, Egypt (Reference  
134 number: ZU-IRB #9241/2-1-2022). We obtained written informed consent from each  
135 respondent after brief information on the purpose of the study was provided to them. To  
136 participate in the study, a respondent must tick the consent box in the mobile application

137 (ODK). Participation in this survey was voluntary and without prejudice, as participants could  
138 withdraw from the survey at any time.

## 139 **2.2 Study Participants and survey methodology**

140 This study presented the preliminary findings from a larger study that was conducted as a cross-  
141 sectional online survey of HCWs across Africa between the 20<sup>th</sup> of December 2021 to 12<sup>th</sup> of  
142 January 2022. HCWs included anyone that provides health services and advice based on formal  
143 training and experience. Hence, they included physicians, nurses, veterinarians, etc. The  
144 questionnaire was designed using Google Forms (Google incorporated) and administered via  
145 online social media platforms such as WhatsApp, Facebook, and E-mails. Our inclusion criteria  
146 were age (18 years and above), location (Africa), and occupation (healthcare worker). Other  
147 African countries (n=12) with less than 100 respondents were excluded from this preliminary  
148 analysis.

## 149 **2.3 Study variables**

150 This study evaluated four self-reported variables among HCWs in each country. These were:  
151 1). COVID-19 positivity rate, 2). COVID-19 full vaccination rate, 3). awareness of PCC, and  
152 4). prevalence of PCC among HCWs. The COVID-19 positivity rate among HCWs was  
153 essential to understand the prevalence of COVID-19 in HCWs and evaluating the occupational  
154 exposure of HCWs in these countries. The second study variable evaluated the vaccination  
155 coverage of HCWs in these countries. Although HCWs were designated as priority recipients  
156 for the COVID-19 vaccination, acceptance of the vaccine is voluntary. Hence, our interest in  
157 the vaccination status of HCWs. The third variable evaluated the awareness of PCC (especially  
158 its symptoms and clinical presentation). This is crucial to the diagnosis of PCC among patients.  
159 The final study variable evaluated the prevalence of PCC among HCWs. Based on the WHO  
160 case definition, a respondent was classified as having PCC if the individual had a history of

161 probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19,  
162 with symptoms lasting for at least 2 months that could not be explained by an alternative  
163 diagnosis [5]. So, only respondents that fit the four criteria of the WHO case definition of PCC  
164 were regarded as having PCC.

#### 165 **2.4 Questionnaire design**

166 The awareness of PCC among HCWs was assessed using a semi-structured pre-validated  
167 questionnaire. The survey instrument was further validated by three independent academic  
168 examiners to ascertain the content and face validity of the adapted questionnaire as well as  
169 observe for any technical glitches. In addition, the reliability of the survey instrument was  
170 assessed using the Cronbach Alpha test (with a score of 0.72) based on 11 purposefully selected  
171 questions. Finally, the questionnaire was pre-tested among 10 HCWs from each of the four  
172 countries before the deployment of the final version for data collection. The results of the pre-  
173 test were not included in the final analysis.

174 The questionnaire was designed in three of the most common languages in Africa (Arabic,  
175 English, and French). The back-to-back translation was validated by two linguists to ensure  
176 that the intended meaning of each question was not lost. In each of the translations, the  
177 questionnaire was divided into 4 sections: a). Socio-demographic information on HCWs b).  
178 history and course of COVID-19 infection c). Awareness of PCC among HCWs d). Impact on  
179 work performance.

#### 180 **2.5 Data analysis**

181 The data obtained from this survey were analyzed using Statistical Package for Social Sciences  
182 (SPSS) version 26 (IBM Corp., Armonk, N.Y., USA). We conducted descriptive statistics and  
183 summarized the information as frequency and percentages. Chi-square analysis was used to  
184 test for association between the four key study variables (COVID-19 positivity rate, COVID-

185 19 full vaccination rate, awareness of PCC, and the prevalence of PCC) in the four countries.  
 186 Finally, the significant variables (p-value < 0.05) were entered into a logistic regression model  
 187 (univariable and multivariable) to determine the association between the socio-demographic  
 188 variables (age, gender, occupation, and their country of origin) and the outcome variable  
 189 (prevalence of PCC in HCWs). The odds ratios generated from the multivariable logistic  
 190 regression analysis were used for all the inferences in this study.

### 191 3. Results

#### 192 3.1 Healthcare worker demographics

193 A total of 713 HCWs filled out the survey instrument out of which 99% (n=706) gave consent  
 194 and responded to the questionnaire (Table 1). The distribution from the four African countries  
 195 was Egypt (n = 281), Nigeria (n = 210), Somalia (n = 111), and Cameroon (n = 104). Most of  
 196 the HCWs were aged between 18-34 years (75.8%, n=535). Of the respondents, nurses  
 197 represented 36.3% (n=256) and more female respondents were recruited (55.8%, n=394).

198 Table 1. Demographics of HCWs recruited into this study (n=706).

Variables	Number (%)
<b>Nationality</b>	
Cameroon	104 (14.7)
Egypt	281 (39.8)
Nigeria	210 (29.8)
Somalia	111 (15.7)
<b>Occupation</b>	
Dentist	38 (5.4)
Nurse	256 (36.3)
Physician	143 (20.3)
Pharmacist	42 (6.1)
Laboratory technician	74 (6.7)
Veterinarian	79 (11.2)
Others*	74 (6.7)
<b>Age</b>	
18 - 24	283 (40.1)
25-34	252 (35.7)



35-44	125 (17.7)
45-54	36 (5.1)
>55	10 (1.4)
<hr/>	
Gender	
Female	394 (55.8)
Male	301 (42.6)
Prefer not to say	11 (1.6)
<hr/>	
Do you have a known chronic disease?	
No	646 (91.5)
Yes	60 (8.5)

199 *Others\*:* scientific officers, health information technologists, and clinical medical students  
 200 *who work or study in a health facility.*

201

### 202 **3.2 COVID-19 infection among healthcare workers**

203 Of the 706 HCWs included in this survey, 19.5% (n=138/706) tested positive for SARS-CoV-  
 204 2 by real-time polymerase chain reaction (RT-PCR), rapid diagnostic test (RDT), or reverse  
 205 transcription loop-mediated isothermal amplification (RT-LAMP). In addition, 8.4%  
 206 (n=59/706) of the HCWs were probable COVID-19 cases. During their COVID-19 infection,  
 207 22.3% of them had moderate to severe symptoms and were admitted to a health facility (Table  
 208 2). Our findings showed that two-thirds of the HCWs (66.4%, n=469) in these countries have  
 209 received a COVID-19 vaccine and 80.6% (n=378) of those vaccinated had received their  
 210 second dose (fully vaccinated). A quarter of the HCWs (27.5%, n=38) were tested less than a  
 211 month before this survey.

212 **Table 2. History of COVID-19 infection among healthcare workers recruited into this study.**

<b>Variables</b>	<b>Number (%)</b>
<b>1. Have you ever been diagnosed with COVID-19? (n = 706)</b>	
No	568 (80.5)
Yes	138 (19.5)
<b>2. Have you noticed the symptoms of COVID-19 which were not confirmed (probable cases)? (n = 568)</b>	
No	509 (72)
Yes	59 (8.4)
<b>3. When was your last COVID-19 test conducted? (n = 127)</b>	
< 1 month ago	38 (27.5)
2-3 months	13 (9.4)
3-6 Months	20 (14.5)

6-12 months	30 (21.7)
12-18 months	24 (17.4)
>18 months	2 (2.2)
4. Were you admitted to a health facility during your COVID-19 infection? (n = 197)	
No	153 (77.7)
Yes	44 (22.3)
5. Have you received any of the approved COVID-19 vaccines? (n = 706)	
No	237 (33.6)
Yes	469 (66.4)
6. Are you fully vaccinated against COVID-19? (n = 469)	
No	91 (19.4)
Yes	378 (80.6)

213


214 The awareness rate of PCC among the general HCWs was 16.1% (n=114/706) whereas the  
215 awareness rate of PCC among COVID-19-positive HCWs was 55.3 % (n=109/197). Based on  
216 the WHO case definition, more than half of the COVID-19-positive HCWs (58.8%,  
217 n=116/197) were deemed to have PCC and one-third (35.5%, n=70/197) of them noticed  
218 changes in their health status due to the PCC. These changes include the symptoms of PCC  
219 which included headache (58.4%, n=115), fatigue (58.8%, n=116), and muscle pain (39.6%,  
220 n=78). Similarly, 30% (n=59) of the HCWs reported the loss of smell after their COVID-19  
221 infection and 20.8% (n=41) of the HCWs experienced the loss of taste long after their COVID-  
222 19 infection. Other less frequent COVID-19 symptoms experienced by HCWs in the 4 African  
223 countries included rash, pins and needles, and memory problems (Figure 1). Half of the HCWs  
224 (53.3%, n=105) reported that their symptoms of PCC were mostly mild, and only 6.9% of them  
225 (n=14) were admitted due to their PCC or its symptoms (Table 3).

226 Table 3. Structure of PCC among HCWs in four African countries (n=197).

Variable	Number (%)
1. Are you aware of the term “post-COVID-19 condition”? (n = 706)	
No	592 (83.9)
Yes	114 (16.1)
2. Have you noticed any changes in your health status after the COVID-19 infection? (n = 197)	
No	127 (64.5)
Yes	70 (35.5)
3. How would you describe the severity of your PCC? (n = 192)	
Mild/moderate	181 (94.3)
Severe	10 (5.2)

Very severe	1 (0.5)
4. Have you been admitted to a health facility due to the PCC? (n = 197)	
No	183 (93.1)
Yes	14 (6.9)
5. Have you received any treatment for your PCC? (n = 197)	
No	125 (63.4)
Yes	72 (36.6)

227  
228  
229



230  
231 **Figure 1.** Frequency of PCC symptoms among COVID-19-positive healthcare workers from  
232 four African countries, 2022 (n = 197/706).

233 **3.3 Work Performance**

234 Only 29.7% (n=58) of the HCWs who experienced COVID-19 and PCC described their work  
235 environment as more stressful. In addition, 42% (n=83) of them believed that their performance  
236 at work has been affected by their PCC. Approximately half of the HCWs (49.3%, n=97) got  
237 tired faster than usual whereas 16.2% of them (n=32) got more forgetful after their COVID-19  
238 infection (Table 4).

239 **Table 4. Perception of COVID-19 infection and PCC on work performance among**  
240 **HCWs (n=197).**

Variable	Number (%)
1. How would you describe your work environment stress level after experiencing the PCC?	

Less stressful	87 (44)
Same environmental stress level	52 (26.3)
More stressful	58 (29.7)
2. Has your performance at work been affected by your PCC?	
No	114 (58)
Yes	83 (42)
3. On a scale of 5, how severely has the COVID-19 pandemic affected your work as an HCW?	
1	76 (38.8)
2	43 (22)
3	47 (24)
4	23 (11.7)
5	7 (3.5)
4. How has the PCC affected your work performance?	
I get tired faster now	97 (49.3)
I feel less motivated	44 (22.3)
I feel more stressed	49 (24.9)
I have less tolerability	39 (19.8)
I get more forgetful	32 (16.2)
5. Have you received proper support from your workplace?	
No	63 (43.5)
Yes	82 (56.5)

241

### 242 3.4 Post-Covid Condition among African healthcare workers

243 Across the four countries, there were statistically significant differences in the positivity rate  
244 of COVID-19 infection among HCWs, their vaccination rates, their awareness of PCC, and the  
245 prevalence of PCC among HCWs (Table S2). HCWs in Somalia tested more positive for  
246 COVID-19 than HCWs in other countries ( $p < 0.05$ ). However, more HCWs in Nigeria (73.8%,  
247  $n=155$ ) had received full COVID-19 vaccines than in the three other countries ( $p < 0.05$ ). The  
248 highest awareness rate of PCC was in Somalia HCWs where 25.2% of them knew about PCC  
249 (Table S2). The prevalence of PCC among COVID-19-positive HCWs was 58.8% ( $n=116$ ).  
250 However, there were no significant differences in the prevalence of PCC among the vaccinated  
251 and un-vaccinated HCWs ( $p > 0.05$ ).

252 Of the sociodemographic variables, only nationality significantly impacted the prevalence of  
253 PCC among HCWs in Africa. Hence, HCWs in Egypt were more likely (OR:14.57; 95% CI:  
254 2.62, 60.76;  $p = 0.001$ ) to have experienced PCC than HCWs in the three other countries (Table

255 5). This is further evident in the fact that 90.7% (n=49) of the 54 Egyptian HCWs who tested  
256 positive for the SARS-COV-2, experienced PCC.

257 Table 5. Logistic regression analysis of demographic variables that affected the prevalence of PCC among HCWs.

258

Outcome variable	Variable	Baseline category		OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
				Univariable analysis		Multivariable analysis	
Prevalence of PCC among HCWs	Age (years)	18-24	25-34	3.50 (2.17, 5.65)	0.027	0.47 (0.08, 2.71)	<0.001
			35-44	2.27 (1.26, 4.09)		0.86 (0.11, 6.52)	
			45-54	4.00 (1.78, 9.00)		1.70 (1.01, 10.59)	
			>55	6.1 (1.61, 22.81)		0.34 (0.01, 6.01)	
			Admission due to COVID-19	No		Yes	
	Gender	Male	Female	0.89 (0.42, 1.86)	0.322	-	-
	Nationality	Cameroon	Egypt	10.14 (3.00, 34.27)	<0.01	14.57 (2.62, 26.76)	0.002
			Nigeria	3.28 (0.92, 11.78)		3.18 (0.51, 19.78)	
			Somalia	0.78 (0.47, 1.31)		0.82 (0.47, 1.48)	
	Occupation	Physician	Nurse	2.47 (0.87, 6.95)	0.051	-	-
Pharmacist			3.57 (0.94, 13.44)				
Technician			1.91 (0.50, 7.23)				
Veterinarian			0.35 (0.06, 1.83)				
Others			0.59 (0.14, 2.56)				

#### 259 **4. Discussion**

260 Globally, HCWs play vital roles as frontline response personnel during the COVID-19  
261 pandemic, especially in emergency responses, public education, and case management. This  
262 however exposes them to a higher risk of COVID-19. One of the problems associated with the  
263 COVID-19 infection is the persistence of symptoms which is generally referred to as “long  
264 COVID” or “PCC” [5]. Here, we present the first PCC survey that targeted HCWs across four  
265 African countries (Cameroon, Egypt, Nigeria, and Somalia). The COVID-19 pandemic  
266 affected the healthcare system in most African countries.

267 Our findings showed that 19.5% of HCWs who participated in this study had confirmed the  
268 COVID-19 diagnostic test, while 8.4% had COVID-19 symptoms and signs but without a  
269 confirmatory test. Therefore, the prevalence of SARS-CoV-2 infection among the HCWs was  
270 27.9% (n=197) in the aforementioned four African countries. The highest COVID-19 positivity  
271 rate was among Somali HCWs (52.1%).

272 Our results showed a higher prevalence rate than recorded by studies such as those of Galanis  
273 et al., [17] and Gómez-Ochoa et al., [18], where they observed the seroprevalence of SARS-  
274 CoV-2 in African HCWs were around 8.2% and 7-11% in 2021 respectively. However, another  
275 study in the same year observed a wider range of prevalence (0 - 45.1%) of COVID-19 among  
276 HCWs in 11 African countries [19]. A recent meta-analysis reported that 10.1% of COVID-19  
277 patients were healthcare workers (HCWs) [20]. The variability in the prevalence rate of  
278 COVID-19 among HCWs could be attributed to the sensitivities and specificities of the  
279 diagnostic tests used (self-reported vs serosurveillance), the study design, the wave of the  
280 pandemic in each country, the period the samples were taken, and the country-specific  
281 contextual differences. For instance, Muller et al [19] solely relied on rapid antibody diagnostic  
282 tests and their results differed between African countries, with 45.1% of seroprevalence in  
283 Nigeria and 1.3% seropositive prevalence in Egypt by the end of 2021.

284 Our findings showed that among the 197 HCWs who suffered from COVID-19, 58.8% of them  
285 experienced PCC based on the clinical symptoms and the WHO clinical case definition. This  
286 PCC prevalence rate is in line with the reports of Osikomaiya et al. [21] who reported a  
287 prevalence of 40.9% for PCC among the general populace in Lagos, Nigeria in 2020. In the  
288 same vein, a systematic review of 57 studies with more than 250 000 participants by Groff et  
289 al. [22], reported a PCC prevalence of 54% among recovered COVID-19 patients in 2021.  
290 Also, Taquet et al. et al. [23] reported that the prevalence of PCC in the USA was 57% during  
291 the first 6 months after a positive COVID-19 test in the year 2021.

292 In addition, Hyassat D, et al., [24] reported that 59.3% of the healthcare providers in Jordan  
293 reported more than one persisting COVID-19 symptom, and among them 97.5%, 62.6% and  
294 40.9% reported more than one COVID-19 symptom at 1–3, 3–6 and 6–12 months, respectively,  
295 after the acute phase of the infection. This finding is in consonant with our findings. However,  
296 Menges et al. [25] reported a much lower PCC prevalence of 26% within 6 to 8 months in  
297 COVID-19-positive patients. The slightly higher prevalence of PCC in older health  
298 professionals (45-54 years old) than in other age groups could be attributed to the fact that older  
299 persons were usually more symptomatic than others [26].

300 Like other studies across the globe, the most reported symptoms of PCC in this study were  
301 fatigue, headache, malaise, headache, myalgia, cough, and loss of smell among other  
302 symptoms. These symptoms have been the most common among patients diagnosed with PCC  
303 across the globe. For instance, Montenegro et al. [27] and Iwu et al. [28] reported that fatigue,  
304 anosmia, headache, and dyspnoea have been the most complaints among PCC patients. In  
305 addition, Osikomaiya et al. [23] observed that 12.8% of patients with PCC in Nigeria had  
306 persistent fatigability and another 12.8% had a headache after their discharge from the hospital.  
307 In the same vein, fatigue was the most reported symptom among Jordanian HCWs [24]. These  
308 results opined that most PCC manifestations were ongoing COVID-19 symptoms.



309 Our findings showed that a large proportion of the HCWs who participated in this study had  
310 no prior knowledge about PCC as only 16.6% of them were aware of PCC. For instance, Somali  
311 HCWs had the highest awareness rate (25.2%) than the other three countries whilst HCWs  
312 from Cameroon had the least awareness rate of PCC as only 4.8% (n=5/104) of them were  
313 aware of PCC or its symptoms. The differences in the awareness rate of PCC could be due to  
314 the differences in the health systems of each country, the HCW training schedule of each  
315 country, and the occupation of the HCWs. However, the PCC awareness rate was high among  
316 COVID-19-positive HCWs as 55.3% of them were aware of PCC.

317 The COVID-19 vaccination rate was different in the four countries. Study participants from  
318 Cameroon had the lowest vaccination rate as only 17.3% of them were vaccinated. These low  
319 vaccination rates could be because Cameroon has the lowest national COVID-19 vaccination  
320 rates of the four countries (Table S1). Although our findings showed that HCWs from Nigeria  
321 had the highest vaccination rate, Egypt has the highest national COVID-19 vaccination rate  
322 with over 71.8 million vaccinations and 29.3% of its populace fully vaccinated. These results  
323 were supported by a previous study in 34 African countries which showed that only 63% of  
324 their study participants were willing to accept the COVID-19 vaccine [31].

325 More longitudinal research are needed to evaluate the impact of vaccinations on the incidence  
326 of PCC. Our data showed that the vaccination status had no impact on the prevalence of PCC  
327 as there was no significant difference ( $p > 0.05$ ) in the fully vaccinated, partially vaccinated,  
328 and un-vaccinated HCWs. This is contrary to the findings of several studies which reported  
329 that COVID-19 vaccines reduced the likelihood of PCC in COVID-19 patients [32]. In the  
330 same vein, the category of the HCW (dentist, nurses, physicians, laboratory technicians,  
331 veterinarians, and others) was not associated with the prevalence of PCC in the four countries.

332 Besides the clinical manifestations of COVID-19, several studies have reported the  
333 psychological burden of the current pandemic on HCWs irrespective of their SARS-CoV-2  
334 infection status [33-38]. While HCWs know that their profession poses a high infection risk,  
335 most of them were afraid to transmit the disease to their families [39]. Furthermore, other  
336 studies have observed anxiety, stress, exhaustion, and depression, with increasing rates of  
337 burnout among HCWs in Africa especially due to the insufficiency of personal protective  
338 equipment and the limited number of standardized care facilities in most African countries [39-  
339 41].

340 Similar to the findings of these studies, our findings showed that psychological symptoms were  
341 experienced by HCWs in the four African countries included in this study. For instance, 12.2%,  
342 8.6%, and 6.1% of the HCWs had anxiety issues, mood changes, and depression respectively.  
343 This psychological burden could affect the perceived stress level in HCWs. Previously, Salazar  
344 et al. [42], Schwartz et. al. [43], and Chew et. al. [44] reported that the stress level at health  
345 facilities during the pandemic was considered more apparent than pre-pandemic era, with rising  
346 levels of burnout syndrome. Conversely, the majority of the HCWs felt the work environment  
347 have been either less stressful (44%) or no change in the work stress level (26.3%) during the  
348 pandemic compared to the pre-pandemic era, and only 29.7% of the HCWs felt higher stress  
349 level after the pandemic at their workplaces.

350 This general perception among the general HCWs was different from the PCC-affected HCWs,  
351 as 42% of the latter felt that because of their PCC, their work performance has been negatively  
352 affected. For instance, 49.3% of them got easily fatigued, while others were more stressed  
353 (24.9%), and lost their enthusiasm (22.3%). In an international study involving 56 countries,  
354 Davis et al. [45] reported that 45.2% of their study participants (n=3762) required a reduced  
355 workload due to ongoing symptoms of PCC. In addition, Twycross, A. [46] opined that the

356 current support scheme for healthcare professionals with PCC in the UK requires immediate  
357 review.

358 Despite the several challenges of each country's healthcare system, HCWs in this study opined  
359 that their respective work institutions provided their affected professionals with appropriate  
360 work support when they got back to work as reported by 56.5% of our HCWs that had PCC.  
361 Recently, several studies have discussed the importance of modifying the health services  
362 settings in Africa to deliver better care for COVID-19 patients and especially for healthcare  
363 workers in African countries [39, 47-53]. Interestingly, several African countries are making  
364 remarkable strides to handle PCC in Africa [21]. These strides started with the recognition of  
365 PCC, its burdens, as well as its management and control. In addition, Egypt recently established  
366 the first clinic dedicated to PCC patients' care and treatment [54].

367 This study has several limitations. Firstly, the sample size is small and the findings should not  
368 be generalized for each country. In addition, online, self-reported surveys could be biased and  
369 usually skewed toward the younger, urban population with access to the internet. In addition,  
370 since the prevalence of PCC was based on self-reports, there was a high likelihood of  
371 misclassification, misunderstanding of some questions, and over-estimation of the prevalence  
372 of PCC, especially in the probable COVID-19 cases. Despite the limitations of our survey  
373 methodology (which makes it impossible to generalize for the HCWs in each country), we  
374 believe that this study will provide baseline information on PCC among HCWs in Africa.

## 375 **5. Conclusion**

376 This study presented the COVID-19 positivity rate, vaccination rate, awareness of PCC, and  
377 prevalence of PCC among HCWs in four African countries. Generally, HCWs were among the  
378 frontline response team during the COVID-19 pandemic. Therefore, it is essential to protect  
379 HCWs with a focus on improved mental health and psychological well-being and the

380 development of national programmes for the occupational health and safety of HCWs [55].  
381 The COVID-19 positivity rate was high in Nigeria and Somalia. Hence, infection, prevention,  
382 and control measures as well as regular training should be instituted for HCWs in these  
383 countries. The very low COVID vaccination rate in Cameroon is worrying and the relevant  
384 health authorities in Cameroon must improve vaccination uptake, especially among HCWs.  
385 Similarly, the awareness of PCC was lowest among HCWs from Cameroon. So, mass advocacy  
386 campaigns on PCC and its varying implications should be provided for the general public in  
387 Cameroon with an emphasis on HCWs. Finally, HCWs from Egypt had the highest prevalence  
388 of PCC. Hence, adequate medical and psychological support should be provided.

389

390

391

392

393

394

395

396

397

398

399

400

401

402 **Declarations**

- 403 • Ethics approval and consent to participate

404 The ethical approval for this study was obtained from the ethical review board (ERB)  
405 of the Kwara State Ministry of Health, Ilorin, Nigeria (reference number  
406 MOH/KS/EHC/777/502) as well as the ERB of the Faculty of Human Medicine of the  
407 University of Zagazig, Egypt (Reference number: ZU-IRB #9241/2-1-2022). This  
408 study was conducted in accordance with the World Medical Association's Declaration  
409 of Helsinki and written informed consent was obtained from each respondent.

- 410 • Consent for publication

411 Not Applicable

- 412 • Availability of data

413 The datasets used and/or analyzed during the current study are available from the  
414 corresponding author upon reasonable request.

- 415 • Competing interests

416 The authors declare that they have no competing interests.

- 417 • Funding

418 No funding was received for this study.

- 419 • Authors' contributions

420 HE, AIA, IAO, AAA, RM, BFD, MR, and MFYM collected data from these  
421 countries. HE and AIA did the statistical analysis and wrote the draft manuscript.

422 All authors read and approved the final version of the manuscript.

- 423 • Acknowledgements

424 We acknowledge Dr Abubakar Musa Imam for reviewing the manuscript.

425

426

427 Table S1. COVID-19 vaccination status in the four African countries as of 6<sup>th</sup> June.

Country	Population	Total doses given	Fully vaccinated
Cameroon	26.6 million	3.66 million	3.11 million
Egypt	102 million	56.91 million	42.34 million
Nigeria	206 million	112.5 million	69.79
Somalia	15.9 million	8.37 million	7.04 million

428

429 Table S2. Association between the nationality of HCWs and their COVID-19 positivity,  
430 vaccination rate, and awareness of PCC.

Variables	Egypt (n=281)	Nigeria (n=210)	Cameroon (n=104)	Somalia (n=111)	$\chi^2$	p-value
COVID-19 positivity (n=197)	54 (19.2)	70 (33.3)	15 (14.4)	58 (52.3)	13.1	0.001
Full COVID-19 vaccination (n=378)	137 (48.8)	155 (73.8)	18 (17.3)	68 (61.3)	9.3	0.025
Awareness of Post-COVID-19 condition (n=114)	42 (14.9)	39 (18.6)	5 (4.8)	28 (25.2)	5.3	0.002
Prevalence of PCC (n=116)	49 (17.4)	39 (18.6)	12 (11.5)	16 (14.4)	21.2	0.001

431  $\chi$  – Chi-square

432

## 433 References

- 434 1. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19.  
435 Am J Physiol Cell Physiol. 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021.
- 436 2. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard  
437 with Vaccination Data. Available online: <https://covid19.who.int/> (accessed on 8 March  
438 2022).
- 439 3. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines.  
440 Vaccines (Basel). 2021;10(1):62. Published 2021 Dec 31. doi:10.3390/vaccines10010062
- 441 4. WHO (2023). *Coronavirus disease (covid-19) pandemic*, World Health Organization.  
442 Available at: <https://www.who.int/europe/emergencies/situations/covid-19> (Accessed: 15  
443 June 2023).
- 444 5. CDC. National Center for Immunization and Respiratory Diseases (NCIRD), Division of  
445 Viral Diseases, [https://www.cdc.gov/coronavirus/2019-ncov/long-term-](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html)  
446 [effects/index.html](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html). Accessed on 22 February 2022
- 447 6. WHO. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6  
448 October 2021. Available online: <https://www.who.int/publications/i/item/WHO-2019->

- 449 [nCoV-Post COVID-19 condition-Clinical\\_case\\_definition-2021.1](#) (accessed on 8  
450 December 2021).
- 451 7. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical  
452 Spectrum, and Challenges for Primary Healthcare Professionals. *Arch Med Res.*  
453 2021;52(6):575-581. doi:10.1016/j.arcmed.2021.03.010
- 454 8. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk  
455 factors, and treatments. *Infect Dis (Lond).* 2021 Oct;53(10):737-754. doi:  
456 10.1080/23744235.2021.1924397.
- 457 9. Lechner-Scott J, Levy M, Hawkes C, Yeh A, Giovannoni G. Long COVID or post  
458 COVID-19 syndrome. *Mult Scler Relat Disord.* 2021 Oct;55:103268. doi:  
459 10.1016/j.msard.2021.103268.
- 460 10. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection.  
461 *Nature Medicine.* 2022;28(7):1461-1467.
- 462 11. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham  
463 MS, Klaser K, Modat M, Murray B. Risk factors and disease profile of post-vaccination  
464 SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective,  
465 community-based, nested, case-control study. *The Lancet Infectious Diseases.* 2022 Jan  
466 1;22(1):43-55.
- 467 12. Zhao FC, Guo KJ, Li ZR.. Osteonecrosis of the femoral head in SARS patients: seven  
468 years later. *Eur J Orthop Surg Traumatol.* 2013;23(6):671–677. [PubMed] [Google  
469 Scholar]
- 470 13. Das KM, Lee EY, Singh R, et al. . Follow-up chest radiographic findings in patients with  
471 MERS-CoV after recovery. *Indian J Radiol Imaging.* 2017;27(3):342–349. [PMC free  
472 article] [PubMed] [Google Scholar]
- 473 14. Lee SH, Shin H-S, Park HY, et al. . Depression as a Mediator of Chronic Fatigue and Post-  
474 Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. *Psychiatry*  
475 *Investig.* 2019;16(1):59–64. [PMC free article] [PubMed] [Google Scholar]
- 476 15. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis  
477 G, David AS. Psychiatric and neuropsychiatric presentations associated with severe  
478 coronavirus infections: a systematic review and meta-analysis with comparison to the  
479 COVID-19 pandemic. *Lancet Psychiatry.* 2020 Jul;7(7):611-627. doi: 10.1016/S2215-  
480 0366(20)30203-0. Epub 2020 May 18. PMID: 32437679; PMCID: PMC7234781.
- 481 16. Zhang P, Li J, Liu H, et al. . Long-term bone and lung consequences associated with  
482 hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a  
483 prospective cohort study. *Bone Res.* 2020;8(1):8. [PMC free article] [PubMed] [Google  
484 Scholar]

- 485 17. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2  
486 antibodies and associated factors in healthcare workers: a systematic review and meta-  
487 analysis. *J Hosp Infect.* 2021;108:120-134. doi:10.1016/j.jhin.2020.11.008
- 488 18. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM,  
489 Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in Health-Care Workers: A  
490 Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical  
491 Characteristics, and Outcomes. *Am J Epidemiol.* 2021 Jan 4;190(1):161-175. doi:  
492 10.1093/aje/kwaa191.
- 493 19. Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and Risk Factors of  
494 COVID-19 in Healthcare Workers From Eleven African Countries: A Scoping Review  
495 and Appraisal of Existing Evidence. *Health Policy Plan.* 2021 Nov 2;czab133. doi:  
496 10.1093/heapol/czab133. Epub ahead of print. PMID: 34726740; PMCID: PMC8689910.
- 497 20. Sahu A.K., Amrithanand V.T., Mathew R., Aggarwal P., Nayer J., Bhoi S. COVID-19 in  
498 health care workers – a systematic review and meta-analysis. *Am J Emerg Med.*  
499 2020;38:1727–1731.
- 500 21. Osikomaiya B, Erinoso O, Wright KO, et al. 'Long COVID': persistent COVID-19  
501 symptoms in survivors managed in Lagos State, Nigeria. *BMC Infect Dis.* 2021;21(1):304.  
502 Published 2021 Mar 25. doi:10.1186/s12879-020-05716-x
- 503 22. Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh  
504 J.S., Ericson J.E., Ssentongo P., et al. Short-Term and Long-Term Rates of Postacute  
505 Sequelae of SARS-CoV-2 Infection: A Systematic Review. [(accessed on 8 December  
506 2021)];*JAMA Netw. Open.* 2021 4:e2128568. doi:  
507 10.1001/jamanetworkopen.2021.28568.
- 508 23. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-  
509 occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study  
510 of 273,618 survivors of COVID-19. *PLoS Med.* 2021;18(9):e1003773. Published 2021  
511 Sep 28. doi:10.1371/journal.pmed.1003773
- 512 24. Hyassat D, El-Khateeb M, Dahbour A, Shunnaq S, Naji D, Bani Ata E. et al. Post-  
513 COVID-19 syndrome among healthcare workers in Jordan. *East Mediterr Health J.* 2023  
514 Apr 27;29(4):247-253. doi: 10.26719/emhj.23.029.
- 515 25. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS,  
516 Puhan MA. Burden of post-COVID-19 syndrome and implications for healthcare service  
517 planning: A population-based cohort study. *PLoS One.* 2021 Jul 12;16(7):e0254523. doi:  
518 10.1371/journal.pone.0254523. PMID: 34252157; PMCID: PMC8274847.
- 519 26. Davies, N., Klepac, P., Liu, Y., Prem, K., Jit, M., & Pearson, C. et al. (2020). Age-  
520 dependent effects in the transmission and control of COVID-19 epidemics. *Nature*  
521 *Medicine*, 26(8), 1205-1211. doi: 10.1038/s41591-020-0962-9.



- 522 27. Montenegro P, Moral I, Puy A, et al. Prevalence of Post COVID-19 Condition in Primary  
523 Care: A Cross Sectional Study. *Int J Environ Res Public Health*. 2022;19(3):1836.  
524 Published 2022 Feb 6. doi:10.3390/ijerph19031836
- 525 28. Iwu CJ, Iwu CD, Wiysonge CS. The occurrence of long COVID: a rapid review. *Pan Afr*  
526 *Med J*. 2021;38:65. Published 2021 Jan 20. doi:10.11604/pamj.2021.38.65.27366
- 527 29. Elnadi H, Odetokun IA, Bolarinwa O, Ahmed Z, Okechukwu O, Al-Mustapha AI (2020)  
528 Knowledge, attitude, and perceptions towards the 2019 Coronavirus Pandemic: A bi-  
529 national survey in Africa. *PLoS ONE* 15(7): e0236918.  
530 <https://doi.org/10.1371/journal.pone.023691>
- 531 30. Odetokun, I.A., Alhaji, N.B., Akpabio, U., Abdulkareem, M.A., Bilat, G.T., Subedi, D.,  
532 Ghali-Mohammed, I. & Elelu, N. (2022): Knowledge, risk perception and prevention  
533 preparedness towards COVID-19 among a cross-section of animal health professionals in  
534 Nigeria. *Pan African Medical Journal*. 41(20).
- 535 31. Anjorin, A.A., Odetokun, I.A., Abioye, A.I., Elnadi, H., Umoren, M.V., Damaris, B.F.,  
536 Eyedo, J., Umar, H.I., Nyandwi, J.B., Abdalla, M.M., Tijani, S.O., Awiagah, K.S., Idowu,  
537 G.A., Fabrice, S.A.N., Maisara, A.M.O., Razouqi, Y., Mhgoob, Z.E., Parker, S., Asowata,  
538 O.E., Adesanya, I.O., Obara, M.A., Jaumdally, S., Kitema, G.F., Okuneye, T.A.,  
539 Mbanzulu, K.M., Daitoni, H., Hallie, E.F., Mosbah, R. & Fasina, F.O. (2021): Will  
540 Africans take COVID-19 vaccination? *PLoS ONE*. 16(12); e0260575.
- 541 32. Venkatesan, P. (2022). Do vaccines protect from long COVID?. *The Lancet Respiratory*  
542 *Medicine*, 10(3), e30. doi: 10.1016/s2213-2600(22)00020-0
- 543 33. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of  
544 the COVID 19 pandemic on healthcare workers globally: A systematic review. *Psychiatry*  
545 *research*. 2020 Oct 1;292:113360.
- 546 34. Spoorthy MS, Pratapa SK, Mahant S. Mental health problems faced by healthcare workers  
547 due to the COVID-19 pandemic—A review. *Asian journal of psychiatry*. 2020 Jun  
548 1;51:102119.
- 549 35. Tan BY, Chew NW, Lee GK, Jing M, Goh Y, Yeo LL, Zhang K, Chin HK, Ahmad A,  
550 Khan FA, Shanmugam GN. Psychological impact of the COVID-19 pandemic on health  
551 care workers in Singapore. *Annals of internal medicine*. 2020 Aug 18;173(4):317-20.
- 552 36. Temsah MH, Al-Sohime F, Alamro N, Al-Eyadhy A, Al-Hasan K, Jamal A, Al-Maglouth  
553 I, Aljamaan F, Al Amri M, Barry M, Al-Subaie S. The psychological impact of COVID-  
554 19 pandemic on health care workers in a MERS-CoV endemic country. *Journal of*  
555 *infection and public health*. 2020 Jun 1;13(6):877-82.
- 556 37. Vizheh M, Qorbani M, Arzaghi SM, Muhidin S, Javanmard Z, Esmaeili M. The mental  
557 health of healthcare workers in the COVID-19 pandemic: A systematic review. *Journal of*  
558 *Diabetes & Metabolic Disorders*. 2020 Dec;19(2):1967-78.

- 559 38. Yan L, Sun P, Wang M, Song T, Wu Y, Luo J, Chen L. The psychological impact of  
560 COVID-19 pandemic on health care workers: a systematic review and meta-analysis.  
561 *Frontiers in psychology*. 2021;12:2382.
- 562 39. Chersich MF, Gray G, Fairlie L, et al. COVID-19 in Africa: care and protection for  
563 frontline healthcare workers. *Global Health*. 2020;16(1):46. Published 2020 May 15.  
564 doi:10.1186/s12992-020-00574-3
- 565 40. Jalili M, Niroomand M, Hadavand F, Zeinali K, Fotouhi A. Burnout among healthcare  
566 professionals during COVID-19 pandemic: a cross-sectional study. *Int Arch Occup  
567 Environ Health*. 2021;94(6):1345-1352. doi:10.1007/s00420-021-01695-x
- 568 41. Torrente M, Sousa PA, Sánchez-Ramos A, et al. To burn-out or not to burn-out: a cross-  
569 sectional study in healthcare professionals in Spain during COVID-19 pandemic. *BMJ  
570 Open*. 2021;11(2):e044945. doi:10.1136/bmjopen-2020-044945
- 571 42. Salazar de Pablo G, Vaquerizo-Serrano J, Catalan A, et al. Impact of coronavirus  
572 syndromes on physical and mental health of health care workers: Systematic review and  
573 meta-analysis. *J Affect Disord*. 2020;275:48-57.
- 574 43. Schwartz RM, McCann-Pineo M, Bellehsen M, Singh V, Malhotra P, Rasul R, Corley SS,  
575 Jan S, Parashar N, George S, Yacht AC, Young JQ. The Impact of Physicians' COVID-19  
576 Pandemic Occupational Experiences on Mental Health. *J Occup Environ Med*. 2022 Feb  
577 1;64(2):151-157. doi: 10.1097/JOM.0000000000002380
- 578 44. Chew NWS, Lee GKH, Tan BYQ, et al. A multinational, multicentre study on the  
579 psychological outcomes and associated physical symptoms amongst healthcare workers  
580 during COVID-19 outbreak. *Brain Behav Immun*. 2020;88:559-565.  
581 doi:10.1016/j.bbi.2020.04.049
- 582 45. Davis, H., Assaf, G., McCorkell, L., Wei, H., Low, R., & Re'em, Y. et al. (2021).  
583 Characterizing long COVID in an international cohort: 7 months of symptoms and their  
584 impact. *Eclinicalmedicine*, 38, 101019. doi: 10.1016/j.eclinm.2021.101019
- 585 46. Twycross A. Living with long Covid: some reflections 14 months down the line. *Evid  
586 Based Nurs*. 2021 May 26:ebnurs-2021-103449. doi: 10.1136/ebnurs-2021-103449
- 587 47. Loewenson R. COVID-19 in East and Southern Africa: Rebuilding Differently and Better  
588 Must Start Now. *MEDICC Rev*. 2020 Jul;22(3):59-60. doi:  
589 10.37757/MR2020.V22.N3.13.
- 590 48. Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, Venter FWD. Long-  
591 COVID: An evolving problem with an extensive impact. *S Afr Med J*. 2020 Nov  
592 23;111(1):10-12. doi: 10.7196/SAMJ.2020.v111i11.15433.
- 593 49. Randeremana R, Lazoumar RH, Tejiokem MC, et al. Institut Pasteur International  
594 Network's efforts to guide control measures against the coronavirus disease 2019 (COVID-

- 595 19) epidemic among healthcare workers in Africa. *Int J Infect Dis.* 2021;103:525-526.  
596 doi:10.1016/j.ijid.2020.12.032
- 597 50. van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and  
598 long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract.*  
599 2022;39(1):159-167. doi:10.1093/fampra/cmab076
- 600 51. Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle-Income  
601 Countries. *JAMA.* 2020;323(16):1549–1550. doi:10.1001/jama.2020.4169.
- 602 52. Lam MH. Mental morbidities and chronic fatigue in severe acute respiratory syndrome  
603 survivors: long-term follow-up. *Arch Intern Med.* 2009;169(22):2142–2147
- 604 53. Ngai JC, Ko FW, Ng SS, et al. . The long-term impact of severe acute respiratory syndrome  
605 on pulmonary function, exercise capacity and health status. *Respirology.* 2010;15(3):543–  
606 550.
- 607 54. Aiash H, Khodor M, Shah J, et al. Integrated multidisciplinary post-COVID-19 care in  
608 Egypt [published correction appears in *Lancet Glob Health.* 2021 Jul;9(7):e915]. *Lancet*  
609 *Glob Health.* 2021;9(7):e908-e909. doi:10.1016/S2214-109X(21)00206-0
- 610 55. WHO. Keep health workers safe to keep patients safe: WHO [Internet]. *Who.int.* 2020 [cited  
611 20 September 2022]. Available from: [https://www.who.int/news/item/17-09-2020-keep-](https://www.who.int/news/item/17-09-2020-keep-health-workers-safe-to-keep-patients-safe-who)  
612 [health-workers-safe-to-keep-patients-safe-who](https://www.who.int/news/item/17-09-2020-keep-health-workers-safe-to-keep-patients-safe-who)

613

## 614 **Legend**

615 Table S1. COVID-19 vaccination status in the four African countries as of 6<sup>th</sup> March 2022.

616 Table S2. Association between the nationality of HCWs and their COVID-19 positivity,  
617 vaccination rate, and awareness of PCC.

618